Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 3.46 is 46% above its 2-year average of 2.38, near the low end of its 2-year range (0.02–13.04).
As of the fiscal period ended Tuesday, June 30, 2026. 26.34% above its 12-month average of 2.74.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 3.46.
QUICK RATIO (ACID-TEST)
3.46
QUICK RATIO (ACID-TEST) AVG TTM
2.74
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+26.34%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+3.30%
vs the sector median at left
YD Bio Limited Ordinary Shares
Market Cap
$435.61M
Quick Ratio (Acid-Test)
3.46
TTM Avg
2.74
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$438.07M
Quick Ratio (Acid-Test)
6.72
TTM Avg
10.04
3Y Avg
13.74
5Y Avg
16.43
Market Cap
$431.97M
Quick Ratio (Acid-Test)
3.91
TTM Avg
4.41
3Y Avg
5.46
5Y Avg
6.71
Market Cap
$439.55M
Quick Ratio (Acid-Test)
13.99
TTM Avg
3.82
3Y Avg
4.27
5Y Avg
5.98
Market Cap
$442.34M
Quick Ratio (Acid-Test)
12.39
TTM Avg
8.12
3Y Avg
11.14
5Y Avg
10.14
Market Cap
$426.51M
Quick Ratio (Acid-Test)
3.28
TTM Avg
10.55
3Y Avg
42.24
5Y Avg
29.93
Market Cap
$445.71M
Quick Ratio (Acid-Test)
7.35
TTM Avg
8.39
3Y Avg
5.06
5Y Avg
6.73
Market Cap
$424.10M
Quick Ratio (Acid-Test)
3.35
TTM Avg
2.92
3Y Avg
4.56
5Y Avg
5.25
Market Cap
$422.86M
Quick Ratio (Acid-Test)
22.29
TTM Avg
19.64
3Y Avg
11.19
5Y Avg
11.30
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| YD Bio Limited Ordinary Shares (YDES) | $435.61M | 3.46 | 2.74 | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $438.07M | 6.72 | 10.04 | 13.74 | 16.43 |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | 3.91 | 4.41 | 5.46 | 6.71 |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.55M | 13.99 | 3.82 | 4.27 | 5.98 |
| Ovid Therapeutics Inc. (OVID)vs › | $442.34M | 12.39 | 8.12 | 11.14 | 10.14 |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | 3.28 | 10.55 | 42.24 | 29.93 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $445.71M | 7.35 | 8.39 | 5.06 | 6.73 |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | 3.35 | 2.92 | 4.56 | 5.25 |
| Tectonic Therapeutic, Inc. (TECX)vs › | $422.86M | 22.29 | 19.64 | 11.19 | 11.30 |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | 1.37 | 1.43 | 1.40 | 1.53 |
Quick Ratio
3.46
Excludes inventory
Current Ratio
5.23
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 3.46 |
| 2025-12-31 | 4.74 |
| 2025-06-30 | 0.02 |
| 2025-03-31 | 0.02 |
| 2024-12-31 | 13.04 |
| 2024-09-30 | 0.02 |
| 2024-06-30 | 0.03 |
| 2024-03-31 | 0.03 |
| 2023-12-31 | 0.02 |
